Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis

NCT06516458 | Recruiting

• 1 other identifier: STU00221990
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to develop a measurement of walking quality, called Gait Deviation Index (GDI) for people with Multiple Sclerosis (MS).

Conditions

Multiple Sclerosis; Multiple Sclerosis, Secondary Progressive; Multiple Sclerosis Relapse; Multiple Sclerosis, Relapsing-Remitting

Outcome Measures

Primary Outcomes (1)

• Kinematics of the gait cycle

  Joint position of lower limbs during a single cycle of gait

  at the time of session

Secondary Outcomes (1)

• 6 minute walk test

  at the time of session

Study Arms (1)

Observation

Gait quality observation

Diagnostic Test: Camera Based Kinematic Analysis

Interventions

Camera Based Kinematic Analysis DIAGNOSTIC_TEST

Observational Study using Camera Based, Marker Less Kinematic Analysis of gait quality of persons with Multiple Sclerosis

Also known as: OpenCap

Observation

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Persons with multiple sclerosis who can ambulate overground

You may qualify if:

• Diagnosis of relapsing form of MS (including relapsing-remitting MS and secondary progressive MS)
• Able to ambulate overground
• Relapse free for at least 1 month
• Age ≥18 and ≤ 75 years
• Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening

You may not qualify if:

• \- Orthopedic injuries, fractures, surgeries or other conditions affecting locomotor function or weight bearing

Sponsors & Collaborators

• Shirley Ryan AbilityLab: lead

Study Sites (1)

Shirley Ryan AbilityLab

Chicago, Illinois, 60611, United States

RECRUITING

MeSH Terms

Conditions

Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Milap Sandhu, PhD

  Shirley Ryan AbilityLab

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Weena Dee

CONTACT

312-328-7503; wdee@sralab.org

Alex Barry

CONTACT

312-238-1435; abarry@sralab.org

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: July 18, 2024
• First Posted: July 24, 2024
• Study Start: July 1, 2024
• Primary Completion: July 1, 2025
• Study Completion (Estimated): July 1, 2026
• Last Updated: July 24, 2024

Record last verified: 2024-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)